Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...

Biocon bagged US FDA's approval for Kristy, which is a rapid-acting human insulin analog, indicated to improve glycemic ...

Nifty 50 closed the week lower by 0.72%, registering a third consecutive week of losses. Banking sector was among the top ...

Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog, expanding their insulin ...

Currently, Kristy is available in the European Union and Canada markets since 2022. The approval is for the fist and only ...

The US diabetes market presents a substantial opportunity for Biocon Biologics, with 38.4 million people living with diabetes ...

Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog. This rapid-acting insulin ...

As per the company’s regulatory filing, Kristy is currently available in the European Union and Canada markets from 2022.

India Inc. enters a crucial earnings week with major Q1 FY25 results lined up from Infosys, Cipla, Adani Energy, UltraTech, ...

AdvantageClub.ai, the world's first agentic AI platform for employee experience, rewards, and wellness, has crossed a significant milestone--15 million users worldwide.

The US Food and Drug Administration approved, the first rapid-acting interchangeable biosimilar product, Kirsty (insulin ...